Overview
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Eligibility
Inclusion Criteria:
- Participant has completed a prior study with PGN-EDODM1
Exclusion Criteria:
- Abnormal laboratory tests at screening considered clinically significant by the Investigator
- Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry